This article is sponsored content brought to you by Zoetis.
Managing allergic and atopic dermatitis cases can be challenging—the skin is dynamic, and no two patients are the same. The dog owner is your partner on this journey, and designing a treatment plan that they can effectively manage at home is an important part of your success.
Zoetis offers a trusted dermatology portfolio, empowering vets to individualise care for every canine patient and owner. Cytopoint®, Apoquel®, and Apoquel Chewable have proven efficacy and safety, supported by years of clinical use in millions of dogs worldwide. These solutions allow you to confidently recommend tailored approaches for each case, which aids adherence to treatments and supports improved outcomes.
Helping owners to help pets
Owner preferences are central to treatment success. Survey insights reveal that 70% of dog owners prefer Apoquel Chewable over tablets1, with its palatable formulation, this medication makes daily dosing a positive experience for dogs and owners, helping to turn treatment into an enjoyable routine. Cytopoint simplifies chronic skin management by providing lasting itch relief through monthly injections, removing the burden of ongoing daily dosing and improving adherence for many owners. Regular monthly clinic visits for Cytopoint administration also keep owners engaged with their veterinary team, supporting continuity of care.
Considering owner capability and lifestyle when selecting treatment options helps foster compliance and reduces stress for both pets and families. By taking these factors into account, vets can design protocols that are practical and sustainable for each household.2,3
Flexible protocols
Flexible protocols enable vets to adapt treatments to the presenting case. Apoquel’s unique dosing regimen was developed to achieve the optimal balance of efficacy and safety and backed by over a decade of real-world use. It’s fast anti-pruritic action, starting within 3 hours4, and proven anti-inflammatory benefits make it ideal for managing acute flares. Meanwhile, Cytopoint simplifies multimodal care for patients requiring lasting itch-relief.
Selecting the most appropriate treatment plan is a collaborative process, relying on a clear understanding of both the patient’s clinical needs and the owner’s capability. For practical guidance on developing dermatology protocols and choosing the best solution for each dog and owner, scan the QR code to access step-by-step advice for creating effective, individualised care plans.
Trust Zoetis to support you in delivering comfort and confidence throughout every stage of your canine patients’ skincare journey.
References:
1. Outcomes Research Report No. 22INTLORDERM-01-01.
2. Dog owners’ perceptions of the convenience and value of chewable oclacitinib: Quantitative survey data from an international survey. Animals 2024, 14, 952. https://doi.org/10.3390/ani14060952.
3. Maddison JE. Medication compliance in small animal practice. Vet Ireland J. 2011;64(1):39-43
4. Fleck T. et al. Speed of onset of a new chewable formulation of oclacitinib maleate (Apoquel®) in a canine model of IL-31-induced pruritus. J Vet Pharmacol Ther. 2022;45(4):380-384.
Zoetis Australia Pty Ltd. ABN 94 156 476 425. Level 6, 5 Rider Boulevard, Rhodes NSW 2138 © 2025 Zoetis Inc. All rights. MM-44760
